Immune Cell Associations with Cancer Risk. by Palomero, Luis et al.
ll
OPEN ACCESSiScience
ArticleImmune Cell Associations with Cancer RiskLuis Palomero,
Ivan Galva´n-
Femenı´a, Rafael
de Cid, ..., Antonis
C. Antoniou,
Conxi La´zaro,
Miquel Angel
Pujana
aca20@medschl.cam.ac.uk
(A.C.A.)
clazaro@iconcologia.net (C.L.)
mapujana@iconcologia.net
(M.A.P.)
HIGHLIGHTS
Cancer risk genetic
variants linked to immune/
stromal cell tissue content
SH2B3 associated with
BRCA1/2 cancer risk and
immune cell counts
Peripheral immune cell
types linked to breast
cancer age at diagnosis
Palomero et al., iScience July
24, 101296
23, 2020ª 2020 The Author(s).
https://doi.org/10.1016/
j.isci.2020.101296
iScience
Article
Immune Cell Associations with Cancer Risk
Luis Palomero,1 Ivan Galva´n-Femenı´a,2 Rafael de Cid,2 Roderic Espı´n,1 Daniel R. Barnes,3 CIMBA,3
Eline Blommaert,1 Miguel Gil-Gil,4 Catalina Falo,4 Agostina Stradella,4 Dan Ouchi,5,13 Albert Roso-Llorach,5,13
Concepcio´ Violan,5,13 Marı´a Pen˜a-Chilet,6 Joaquı´n Dopazo,6 Ana Isabel Extremera,1 Mar Garcı´a-Valero,1
Carmen Herranz,1 Francesca Mateo,1 Elisabetta Mereu,7 Jonathan Beesley,8 Georgia Chenevix-Trench,8
Cecilia Roux,9 TakMak,9 Joan Brunet,10 Razq Hakem,11 Chiara Gorrini,9 Antonis C. Antoniou,3,* Conxi La´zaro,12,*
and Miquel Angel Pujana1,14,*
SUMMARY
Proper immune system function hinders cancer development, but little is known
about whether genetic variants linked to cancer risk alter immune cells. Here, we
report 57 cancer risk loci associated with differences in immune and/or stromal
cell contents in the corresponding tissue. Predicted target genes show expres-
sion and regulatory associations with immune features. Polygenic risk scores
also reveal associations with immune and/or stromal cell contents, and breast
cancer scores show consistent results in normal and tumor tissue. SH2B3 links pe-
ripheral alterations of several immune cell types to the risk of this malignancy.
Pleiotropic SH2B3 variants are associated with breast cancer risk in BRCA1/2mu-
tation carriers. A retrospective case-cohort study indicates a positive association
between blood counts of basophils, leukocytes, andmonocytes and age at breast
cancer diagnosis. These findings broaden our knowledge of the role of the im-
mune system in cancer and highlight promising prevention strategies for individ-
uals at high risk.
INTRODUCTION
The immune system maintains organismal integrity and function by continuously protecting itself from
exogenous and endogenous assaults. The concept of ‘‘immunological surveillance of cancer’’ was first pro-
posed by Burnet in 1970 (Burnet, 1970) and developed by Thomas about a decade later (Thomas, 1982). In
this theory, the immune system inactivates or eliminates cancer-prone cells that are detected early in
normal tissue (Ribatti, 2017). Although this idea remains a matter of debate, it is clear that some immune
factors decisively influence cancer development and progression. Immunosuppression due to primary im-
munodeficiency or due to therapies administered to prevent organ transplant rejection and certain virus
infections are associated with an increased risk of some cancers (Mortaz et al., 2016). In parallel, studies
of mouse models with defined genetic alterations have demonstrated the relevance of immunosurveil-
lance; for example, loss of Nkg2d, which encodes the activating receptor of natural killer (NK) and
T cells, increases the risk of spontaneous neoplasms (Guerra et al., 2008).
Results from genome-wide association studies (GWASs) have identified risk-associated variants in loci cod-
ing for immune regulatory factors, such as NKG2D for cervical cancer risk (Chen et al., 2013). Indeed,
pathway-based analyses of GWAS results have highlighted the involvement of immune-related processes
in susceptibility to certain cancer types (Michailidou et al., 2017). In parallel, many germline genetic variants
can influence immune cell infiltration in tumors (Lim et al., 2018). Therefore, immune-centered investiga-
tions of normal or precancerous tissue could yield fundamental evidence for improving cancer risk estima-
tion and prevention (Spira et al., 2017). However, whether common genetic variants linked to cancer risk
alter immune cell contents in the corresponding cancer target tissue, and/or at the systemic level, remains
largely undetermined.
The balance between immunological surveillance and tolerance is determined from a complex interplay
between different types of immune cells and other classes of stromal cells (Vinay et al., 2015; Gonzalez
et al., 2018). Here, we describe an integrative analysis of genetic and transcriptome data from tissue
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defined as normal and located adjacent to surgically removed tumors, and from primary tumors analyzed
by The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research Network et al., 2013). This enables
us to identify immune and stromal (hereafter ‘‘immune/stromal’’) cell tissue content associations with the
risk of several human cancer types. Beyond single variants, polygenic risk scores (PRSs) also show associ-
ations with differences in inferred immune/stromal cell tissue contents. Consistent associations among im-
mune cell signatures, PRSs, and age at diagnosis suggest that higher immune cell infiltration reduces the
risk of breast cancer. We identify the lymphocyte SH2B adaptor 3 (LNK/SH2B3) locus as linking immune cell
counts and breast cancer risk, including that from BRCA1/2 mutation carriers. To evaluate this connection
further, we assess associations between breast cancer age at diagnosis and immune cell counts measured
at diagnosis in routine clinical blood tests; the results further suggest that peripheral immune cell status
influences breast cancer risk. Collectively, these findings may broaden our current knowledge of the bio-
logical basis of cancer risk and thereby suggest strategies for cancer prevention.
RESULTS
Strategy to Evaluate Immune/Stromal Cell Tissue Contents that Influence Cancer Risk
TCGA has greatly increased our knowledge of human cancer through multilayer biological analyses, which
include genetic and gene expression profiling of tissue considered to be normal and situated adjacent to
the cancer (hereafter referred to as ‘‘normal’’) and primary tumors (Liu et al., 2018). In parallel, many suc-
cessful GWASs have identified hundreds of germline genetic variants associated with the risk of common
cancer types (Torkamani et al., 2018). By compiling GWAS results, we assigned cancer risk variants to 17
TCGA projects based on tissue of origin correspondences (Figure 1A lists the cancer study acronyms,
and Table S1 lists the cancer risk variants). As deconvolution analyses of bulk gene expression enable
robust inference of cell type content in heterogeneous samples (Avila Cobos et al., 2018), deduced cell
content in normal tissue and tumors can be assessed for associations with cancer risk variants in multivar-
iate analyses (Figure 1B). Moreover, as differences in cancer risk are more accurately defined by combina-
tions of key variants in PRSs (Torkamani et al., 2018), it might be possible to better define the relevance of
the immune/stromal cells by analyzing associations between PRSs and their corresponding signatures (Fig-
ure 1C; Table S2 summarizes the number of normal tissue and primary tumor samples available for each
subsequent analysis).
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Figure 1. Strategy for Assessing the Effect of Immune/Stromal Cell Tissue Content on Cancer Risk
(A) TCGA cancer projects analyzed in this study and data analysis workflow.
(B) Association between gene expression-inferred immune/stromal cell tissue content and GWAS-identified risk variant.
(C) Association between gene expression-inferred immune/stromal cell tissue content and cancer PRS.
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To infer immune/stromal cell contents in normal and primary tumor samples using bulk tissue RNA
sequencing (RNA-seq) data from TCGA, we applied a consensus-signature approach benchmarked
against other methods (ConsensusTME; Jime´nez-Sa´nchez et al., 2019). Using this approach, the computed
immune/stromal estimations in the 17 identified TCGA datasets were typically found to be positively
correlated with two other methods (Figure S1), as well as with estimates of leukocyte content measured
by a different method (Taylor et al., 2018) (Figure S2). In turn, the estimates were generally found to be
negatively correlated with aneuploidy (Figure S3), as expected (Taylor et al., 2018). In addition, the im-
mune/stromal cell TCGA estimates showed significant differences between primary tumors with low or
high levels of CD274/PDL1 and CD279/PDCD1 expression (Figures S4 and S5). Applying the method
to RNA-seq data from whole blood samples of healthy adults also revealed positive correlations with im-
mune cell enumerations using fluorescence-activated cell sorting (Newman et al., 2019) (Figure S6).
Moreover, the estimates from this method were found to be highly correlated (Spearman’s r > 0.75)
with the numbers of immune/stromal cells used to generate 100 pseudo-bulk breast tumors (Figure S7
and Methods).
To further assess the validity of the inferred immune cell contents in TCGA, the deduced scores for each
setting were assessed for associations with defined immune benchmark genes (Methods). In most set-
tings, each inferred immune cell type content was found to be positively correlated with the expression
of the assigned benchmark; the average Pearson’s correlation coefficient values for all signature-bench-
mark pairs were 0.52 and 0.60 in the normal tissue and primary tumor sets, respectively (Figure S8 and
Table S3). To assess further the coherence of the inferred immune cell contents, the corresponding
scores were tested for association with the activity status of immune-related signaling pathways (Cubuk
et al., 2018). This analysis revealed coherent clustering of immune and stromal cell types in normal tissue
(Figure S9).
Identification of Cancer Risk Variants Linked to Differences in Immune/Stromal Cell Tissue
Content
A total of 1,453 cancer risk variants were compiled from various sources; 214 of these were directly genotyped in
TCGA, and the rest were imputed. After applying quality controls and filtering criteria (Methods), 627 and 966
variants were analyzed as potential immune/stromal quantitative trait loci (isQTLs). The isQTLs were identified
usingmultivariate regressions including covariates of gender (when informative), age at diagnosis, tumor stage,
and histology. The significance of the associations in each setting was concluded from 1,000 permutations
(Methods). Tumor data were also analyzed because germline risk alleles are frequently associated with defined
cancer histopathological and biomarker features (Michailidou et al., 2017). To avoid redundant tests, only cell
signatures with eigenvalues >1 were examined in each setting (Table S4). Through this methodology, 22 signif-
icant isQTLs were identified. These comprised normal tissue corresponding to esophageal carcinoma (ESCA),
lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carci-
noma (UCEC), and primary tumors of breast cancer (BRCA), head and neck squamous cell carcinoma
(HNSC), LUSC, and ovarian serous cystadenocarcinoma (OV) (Figure 2A and Table S5).
Several of the identified isQTLs involved differences in endothelial and fibroblast cell content (Table S5), and
these signals may also indicate links with immune cell differences: for instance, rs4072037 is associated with
endothelial cell content in normal esophageal tissue, and this variant corresponds to a cis-expression (cis-e)
QTL in several normal tissue types (GTEx Consortium, 2013) of genes whose products are functionally relevant
in the immune system and biology of endothelial cells (Stenina-Adognravi, 2014), includingGBA,GBAP1, TSP3/
THSB3, andMUC1, which are locus-mapped genes. In addition, the cancer pleiotropy rs11168936 variant (Feh-
ringer et al., 2016) is associated with differences in fibroblast content in normal lung tissue corresponding to
LUSC, and this variant is a cis-eQTL for C1QL4 in several normal tissue types (GTEx Consortium, 2013). Intrigu-
ingly, C1q is a regulator of dendritic cell maturation (van Kooten et al., 2008), andwe found this variant also to be
associated with dendritic cell content (Figure 2B). In normal lung tissue corresponding to LUAD, rs17078110 is
associated with B cells, and this locus codes for SASH1, a regulator of TLR4 signaling and cytokine production
(Dauphinee et al., 2013). Among the isQTLs identified in tumors, rs3764419 is associatedwith cytotoxic cell con-
tent in OV. This variant is a cis-eQTL for ATAD5 (GTEx Consortium, 2013), whose product is essential for proper
B cell biology and immunoglobulin production (Zanotti et al., 2015). Overall, these data suggest that some can-
cer risk variants are associated with immune/stromal cell tissue content, and that this link is mediated by alter-
ations in genes of functional importance to the immune system.
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Identification of Cancer Risk Variants Associated with Immune System Functions in Target
Tissue and Primary Tumors
The TCGA consortium examined 160 immune system-related gene expression signatures across hundreds
of tumors and identified five of them as being informative for cancer classification: IFN-g response, lympho-
cyte infiltration score, macrophage regulation, TGF-b response, and wound healing (Thorsson et al., 2018).
Therefore, we sought to expand on the aforementioned cell-type-based associations by analyzing these
five additional signatures using the same method as introduced earlier: multivariate regression with signif-
icance determined from 1,000 permutations. This study identified 75 isQTLs, of which 11 variants had been
identified in the previous isQTL analyses, which represents a significant concordance (Fisher’s exact test,
p < 0.0001; Figure 2C and Table S6). Taking both analyses into account suggests that the risk of 13 cancer
types may be influenced by immune/stromal cell tissue content.
Of the 57 unique variants identified from all isQTLs, five were linked to tumor suppressor genes with recog-
nized roles in the immune system: CDKN2A/B, DCC, MUC1, and SASH1. In addition, genomic enhancers
identified in T helper, regulatory, effector, memory, and mononuclear cells were significantly over-repre-
sented in this unique variant set relative to all human variants: > 2-fold enrichments, binomial test p values
<0.05 (Ward and Kellis, 2012). Consistent with this observation, 8 (14%) variants corresponded to expres-
sion (e) QTLs from 18 immune-related genes in normal human tissue (GTEx Consortium, 2013) and 13
(25%) corresponded to eQTLs identified in CD4+ and/or CD8+ T cells (Kasela et al., 2017) (Tables S5
and S6). To evaluate the relevance of these observed percentages, we examined the expected proportions
when considering all cancer risk variants studied; lower percentages were identified in both analyses, with
expected proportions of 11% (115/1,079) for eQTLs of immune-related genes in normal human tissue (GTEx
Consortium, 2013) and 14% (151/1,079) for eQTLs in CD4/8+ T cells (Kasela et al., 2017). We then examined
whether the eQTL gene targets documented within the isQTLs were functionally coherent by determining
the proportion of significant gene expression-immune/stromal cell signature correlations and comparing
the results with those from equivalent 1,000 random gene sets. Both isQTL sets (Tables S5 and S6) included
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a higher proportion of eQTL gene targets that were positively correlated with immune/stromal cell signa-
tures than expected by chance (Figure S10). Finally, variants correlated (r2 > 0.8) with each isQTL were in-
tersected with various functional genomic data from B cells, monocytes, and CD4+ and CD8+ T cells, and
for potential effects on protein coding sequences (Methods). These analyses identified two additional
candidate genes (LIF and OSM) with established functions in the immune system, being involved in cyto-
kine signaling (Table S7). Together, these data indicate that a substantial proportion of the isQTLs identi-
fied influence genes whose expression is associated with immune system functions.
PRS Associations with Immune/Stromal Cell Tissue Content Highlight Breast Cancer Risk
The effects of individual cancer risk variants are generally small, but their combinations within PRSs can
potentially identify individuals who are at substantially higher risk than average for the population (Torka-
mani et al., 2018). Therefore, reported PRSs were computed in the corresponding normal tissue and pri-
mary tumor TCGA settings and evaluated for associations with immune/stromal cell contents using multi-
variate analyses as described earlier. The study of normal tissue was limited to breast. Despite the valuable
TCGA resource, the available sample size sets limited the detection of nominal significant associations to
those with correlation coefficients of r > 0.3 in normal breast and of r > 0.12 in BRCA; higher correlations
would be required for all other normal or tumor settings (Figure S11).
In normal breast, most immune/stromal cell contents tended to be negatively correlated with the corre-
sponding PRSs; the PRS cell signature correlation coefficients for overall and estrogen receptor (ER)-pos-
itive breast cancer were significantly less than zero (p values <0.001; Figure 3A). The ER-negative PRS could
not be computed because of the relatively low number of normal samples of this subtype and with com-
plete data. Analogous limitations were encountered when attempting to analyze triple-negative breast
cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive breast cancers, and there
were no HER2-specific PRSs to analyze whatsoever. Potentially protective cell types (i.e., those exhibiting
a nominally significant negative correlation between cell content and PRS) in the aforementioned two
breast cancer settings included dendritic cells, eosinophils, macrophage M2, monocytes, neutrophils,
and T cell terminal differentiation (Figure 3A).
In addition to the breast cancer PRSs, eight other scores (Fritsche et al., 2018) were examined in their cor-
responding primary tumor TCGA settings. The distribution of the correlation coefficients between im-
mune/stromal cell tissue content and the PRS was again found to be less than zero not only in BRCA but
also in in glioblastoma multiforme (GBM; with a major contribution for fibroblast content) and thyroid car-
cinoma (THCA; Figure 3B). Conversely, positive correlations were detected in bladder urothelial carcinoma
(BLCA), OV, prostate adenocarcinoma (PRAD), skin cutaneousmelanoma (SKCM), and, principally, in LUAD
and LUSC (Figure 3B). Conversely, positive correlations were detected in BLCA, serous OV, PRAD, SKCM,
and, principally, in LUAD and LUSC (Figure 3B). Therefore, risk stratification based on PRSs may also be
linked to differences in immune/stromal cell content in normal and/or tumor tissue. LUAD and LUSC
PRSs shared positive correlations (p < 0.05) with cytotoxic and NK cell tissue contents; however, these as-
sociations may be influenced by smoking status, because LUAD current smokers showed an opposite trend
(Figure S12).
Combined analyses of normal tissue and primary tumor data further suggested common protective effects
for high immune cell content in breast and colorectal tissue, and also potentially in brain and a few other
settings (Figure 3C). In contrast, high immune cell content might principally increase the risk of lung,
bladder, and pancreatic cancer (Figure 3C), although, as already noted, smoking may influence these as-
sociations. Then, analyses of COAD subtypes (Methods) suggested protective effects for high immune
cell content in genomic stable tumors (Figure 3D, left panel), but this association might be biased due
to PRS development in overall incident cases. When analyzing the COAD molecular subtypes, lower risk
of CSM3 might also be associated with higher immune cell content (Figure 3D, right panel). The sample
sets of these subtype analyses were relatively small to obtain robust conclusions, but, when compared
with normal colorectal tissue, an opposite trend was observed (Figure 3D, left panel), which suggests
that immune cell infiltration has different roles between normal tissue and tumors.
As described earlier, the normal breast and BRCA settings both showed PRS-cell signature negative cor-
relations. To assess these observations further, the correlation estimates were compared with
those from similar analyses using age at diagnosis instead of the PRSs. In normal breast tissue, the
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Figure 3. Associations between Immune/Stromal Cell Signatures and PRSs
(A) Unsupervised clustering of the results of the regression analysis between cell signatures and PRSs in normal breast
tissue. The y axis depicts the cell type signatures, and the x axis shows the PRSs. Sources #1 and #2 of the PRSs are detailed
in Methods. ER+ and ER indicate estrogen receptor-positive and estrogen receptor-negative subsets, respectively. The
maximum sample size used in each analysis is shown. The color scale (t-score) is calculated as the b estimate divided by
the standard error. Nominally significant associations are indicated by black-outlined rectangles.
(B) Unsupervised clustering of the coefficients of the regression of cell signature values in primary tumor TCGA studies
and the corresponding PRSs. The gray-filled rectangles indicate ‘‘not tested’’ correlations because the corresponding cell
signatures were only defined for breast cancer.
(C) Unsupervised clustering of the coefficients of the regression of cell signature values in combined normal tissue and
primary tumor datasets, and the corresponding PRSs. The regression p values <0.01 are also indicated as depicted in the
inset.
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immune/stromal cell contents tended to show positive correlations with age at diagnosis (p < 0.001; Fig-
ure 3E). Consequently, negative correlations were detected between the estimates from the two parallel
analyses, considering all cases or solely ER-positive cases (Figure 3F). Therefore, relatively higher im-
mune/stromal cell content in normal breast might be a factor protecting against development of
malignancy.
SH2B3 Connects Immune Cell Tissue Content with Breast Cancer Risk
The identified cancer risk isQTLs could be explained by peripheral alterations in immune cells. Examination
of GWAS results for blood cell traits revealed that the tumor COAD isQTL rs12412391 in chromosome 10
(Table S6) is in linkage disequilibrium (r2 = 0.93) with rs11190133, which is associated with differences in
platelets in the UK Biobank study (Astle et al., 2016). These variants constitute an eQTL of NKX2-3 (GTEx
Consortium, 2013), and, remarkably, loss of the mouse ortholog causes developmental alterations in the
spleen, colonic crypts, and lymphocyte tissue homing (Pabst et al., 1999). In addition to this locus, the tumor
BRCA isQTL rs11065979 in chromosome 12 (Table S5) was associated with blood count differences in ba-
sophils, erythrocytes, eosinophils, leukocytes, monocytes, and neutrophils in the UK Biobank study (Astle
et al., 2016) (Table S8). The same study also indicated an association with breast cancer risk (p = 0.0003;
Table S8). This variant has also been linked to cancer pleiotropy (Fehringer et al., 2016) and psoriasis
(Tsoi et al., 2017), among other traits (GWAS Catalog). A variant in linkage disequilibrium, rs3184504
(r2 = 0.89), had also been associated with breast cancer risk (Fehringer et al., 2016), serum IgA levels (Jons-
son et al., 2017), and various autoimmune diseases (Webb andHirschfield, 2016), among other traits (GWAS
Catalog).
To investigate further the role of the isQTL identified in chromosome 12 and linked to breast cancer risk, we
analyzed association results from BRCA1/2 mutation carriers. Both depicted variants showed nominal as-
sociations with breast cancer risk in women carriers of germline BRCA1 or BRCA2 mutations: BRCA1 mu-
tation carriers, rs11065979 hazard ratio (HR) = 0.96, 95% confidence interval (CI) 0.92–0.99, p = 0.018;
rs3184504 HR = 0.95, 95% CI 0.92–0.99, p = 0.006; BRCA2 mutation carriers, rs11065979 HR = 0.94, 95%
CI 0.90–0.99, p = 0.019; and rs3184504 HR = 0.93, 95% CI 0.89–0.98, p = 0.003. Then, wider examination
of this region in chromosome 12 identified several genetic associations (p < 0.01) with breast and/or ovarian
cancer risk in these women (Figure 4A and Table S9).
The chromosome 12 locus identified here includes many eQTL signals for SH2B3 in EBV-transformed lym-
phocytes and normal tissue (Figure 4A, bottom panel). Next, to evaluate potential causality linked to
SH2B3, complementary gene expression analyses were performed using the normal breast tissue TCGA
data. First, the expression of SH2B3 was found to be positively correlated with most of the immune cell/
stromal cell signatures (Figure 4B); second, SH2B3 expression was also found to be positively correlated
with age at diagnosis, adjusted for tumor stage and regardless of cancer subtype (Figure 4C); third, an
84-gene signature corresponding to gene and protein functional relationships with mouse Sh2b3 and/or
human SH2B3 (Huan et al., 2015) was also positively correlated with age at diagnosis (Figure 4D); and
last, SH2B3 expression was positively correlated with the protein measures of CD26, cell surface glycopro-
tein receptor important for T cell activation (Klemann et al., 2016), and TFCR, transferrin receptor required
for erythropoiesis and immune system development (Jabara et al., 2016) (Figure 4E). In addition, the asso-
ciation between SH2B3 expression in normal breast and age at diagnosis was replicated in an independent
dataset (Terunuma et al., 2014): n = 47, r = 0.30, p = 0.039. Therefore, an identified isQTL may influence
breast cancer risk through perturbation of SH2B3 expression, which is expected to be fundamental for ac-
curate systemic development and function of immune cell populations (Li et al., 2000; Velazquez et al.,
2002; Jabara et al., 2016).
Figure 3. Continued
(D) Unsupervised clustering of the coefficients of the regression analysis between PRSs and cell signatures in combined
normal tissue and primary tumors of the COAD study, divided by cancer subtypes.
(E) Unsupervised clustering of the results of the regression analysis of cell signatures in normal tissue and age at diagnosis
across TCGA studies. Associations significant at a false discovery rate (FDR) < 5% are indicated by black-outlined
rectangles.
(F) Negative correlations between the coefficients of regressions of immune/stromal cell contents and age at diagnosis or
PRSs in normal breast tissue, for all cases and only ER-positive cases. The correlation coefficients are shown.
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Peripheral Immune Cell Counts Are Associated with Breast Cancer Risk
To assess the proposed link between breast cancer risk and peripheral immune cell counts, which in turn
might be influenced by specific genetic variants and gene candidates, a retrospective case-cohort study
was performed. Data on age at diagnosis, tumor stage and subtype, and blood test results from 259 breast
cancer cases were compiled in a tertiary referral hospital (Methods). The cases were randomly selected
from clinical health records and showed an average age at diagnosis of 55.6 years, 95% CI 54.0–57.1 years.
The blood test data were those collected on the date closest to diagnosis: 6 patients had the blood test on
the same date as their diagnosis, 40 were earlier (on average 40 days before), and 182 were later (on
average 45 days later): the average time between the blood test and disease diagnosis was 23.9 days,
95% CI 16.3–31.5 days. Amultivariate regression analysis including tumor stage and subtype revealed three
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(A) Graph showing the chromosome 12 association results (-log10 p value, y axis) with breast and ovarian cancer risk (as
depicted in the inset) in women carriers of BRCA1/2 mutations. The rs3184504 and rs11065979 variants are indicated.
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(C) Positive correlation between SH2B3 expression in normal breast and age of diagnosis of breast cancer. The trend lines
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value from the multivariate regression analysis is shown.
(D) Positive correlation between SH2B3 functionally related gene set in normal breast and age of diagnosis of breast
cancer.
(E) Positive correlation between SH2B3 expression and CD26 and TFRC protein expression as measured by TCGA
reverse-phase protein array (RPPA) assays. The correlation p value from the multivariate regression analysis is shown.
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immune cell types to be significantly (p < 0.05) positively correlated with age at diagnosis: basophils, leu-
kocytes, and monocytes (Figure 5). The trends were consistent for different tumor stages (0–2 and 3–4) and
the major cancer subtype (i.e., luminal); the smaller patient sets of HER2-postive breast cancer (n = 18) and
TNBC (n = 17) showed greater variability (Figure 5). The neutrophil to lymphocyte ratio, which is an estab-
lished rate associated with breast cancer prognosis (Ethier et al., 2017), was not found to be associated with
age at diagnosis in this study (p = 0.65).
DISCUSSION
The results of this study support the idea that the risk of certain cancers is influenced by the content of im-
mune/stromal cells in the target tissue and/or by differences in peripheral immune cell counts. Of the 17
cancer settings analyzed, 57 risk loci comprising 13 cancer types were associated with differences in im-
mune/stromal cell content with respect to the corresponding normal tissue and/or primary tumors. The
gene candidates linked to these associations include several with key functions in the immune system,
and they show significant enrichments in immune-related regulatory features and expression profiles.
Detection of associations between immune/stromal cell signatures and PRSs provide further evidence
that differences in these cell contents influence cancer risk. Nevertheless, the role of some cell types is
multifaceted; for example, endothelial cells can regulate trafficking and activation of immune cells in a
given tissue, but, critically, also determine angiogenesis (Hendry et al., 2016). Similarly, a given genetic
variant may influence the expression of more than one gene target and/or indirectly alter the immune sys-
tem by different mechanisms, such as by provoking oncogenic-induced signals.
Unexpectedly, there appear to be opposing cancer risk effects for immune cell contents across cancer
types. These might be due to differences in tissue microenvironment conditions, such as inflammation
caused by smoking or other factors (Shalapour and Karin, 2015). However, the study was limited by the rela-
tively low numbers of normal tissue samples available for analysis, and, potentially, by gene expression al-
terations in normal tissue adjacent to neoplasms. This study had more power to detect significant results in
normal breast tissue and BRCA and, consequently, the results prove to be more relevant and coherent in
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Figure 5. Positive Correlation between Peripheral Immune Cell Counts around Time of Diagnosis and Breast
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retrospective case-cohort hospital-based study. The value of p shown here is that associated with the coefficient
calculated as part of the multivariate regression analysis. The trends for tumor subgroups are shown as depicted in the
inset.
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these settings. Carrying out similar analyses in other normal and cancer tissue contexts would appear to be
worthwhile. Such additional studies would benefit from complementary molecular marker and signaling
analyses, which would definitively establish the functional consequences of inferred cell alterations.
At the same time as providing insight into the biological basis of cancer initiation, this study yields data that
could be useful for analyses of cancer risk and prevention. Associations of PRSs with immune cell signatures
could inform preventive strategies by modulating specific cell functions and/or their signaling molecules in
individuals at high risk (Spira et al., 2017). This idea is particularly relevant in breast cancer. Our study shows
consistent associations between immune/stromal cell signatures andbreast cancer PRSs or age at diagnosis
in normal tissue. A recognized risk locus connects differences inmost peripheral immune cell types to breast
cancer risk. This locus harbors the SH2B3 gene, which is altered in hematological neoplasms and autoim-
mune diseases (Maslah et al., 2017, p. 3). Common genetic variation at this locus has been linked to cancer
pleiotropy, including breast cancer susceptibility (Hung et al., 2015; Fehringer et al., 2016).We extend these
observations by identifying potential associations with breast and ovarian cancer risk in BRCA1/2mutation
carriers. Our study shows consistent expression correlations of SH2B3 or SH2B3 functionally related genes
with age at diagnosis using normal breast tissue data. Thus, pharmacological enhancement of SH2B3 func-
tion might reduce cancer risk in individuals with high PRSs and/or carriers of BRCA1/2mutations. However,
the functional impact on SH2B3 remains to be established, and, therefore, prospective studies determining
the expression and/or functional differences of SH2B3 among individuals with specific alleles in the corre-
sponding locus, and their associations with peripheral immune cell counts and cancer risk, are needed.
The effect of systemic differences of immune cell counts on breast cancer risk is further supported by un-
expected associations between basophil, leukocyte, and monocyte blood counts and age at diagnosis
from a retrospective case-cohort study. Relatively low monocyte counts collected over a 1-year period of
disease diagnosis have recently been associated with increased breast cancer risk (Kresovich et al.,
2020). However, high baseline leukocyte counts in a prospective study of postmenopausal women were
found to be associated with increased breast cancer incidence (Margolis et al., 2007). In our study, we
aimed to assess whether individuals’ status of having relatively low peripheral immune cell counts was asso-
ciated with initial cancer development, hypothetically due to reduced immunosurveillance. Our results are
consistent with this explanation, and among other factors, altered SH2B3 function might give rise to these
observations. As a whole, the results of this study may be useful for improving cancer risk estimation, and
for identifying preventive approaches.
Limitations of the Study
The present report identifies cancer-associated genetic variants and polygenic risk scores linked to the
alteration of immune and/or stromal cell systemic and/or tissue contents. These links could explain the
greater cancer risk. However, the study has several limitations that should be borne in mind. The cell con-
tent inferences were based on gene expression profiles, and therefore, molecular and cellular analyses are
required to corroborate them and accurately assess their functional consequences. The observed associ-
ations could also be indirect in some instances. The study was also limited by the original sample sets, and
observed associations could be confounded by other factors, such as the level of tissue inflammation, in-
dividual hormonal status, and lifestyle aspects. The genetic basis of the proposed associations between
blood cell count and age at breast cancer diagnosis in the studied cohort remains unknown, and it is un-
clear whether similar associations exist in BRCA1/2 mutation carriers.
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Supplementary figures legends 
Fig. S1. Evaluation of immune/stromal cell tissue content estimates in 
relation to two other methods. Related to Figure 1. 
(A) Heatmap showing the correlations (Spearman’s ρ) between ConsensusTME-
based values and analogous TIMER cell type estimates. 
(B) Heatmap showing the correlations (Spearman’s ρ) between ConsensusTME-
based values and analogous MCP-counter cell type estimates. 
 
Fig. S2. Evaluation of immune/stromal cell tissue content estimates in 
relation to independent leukocyte estimates. Related to Figure 1. Heatmap 
showing the correlations (Spearman’s ρ) between ConsensusTME-based values 
and independent leukocyte estimates using the approach of Taylor et al. (2018). 
 
Fig. S3. Evaluation of immune/stromal cell tissue content estimates in 
relation to aneuploidy scores. Related to Figure 1. 
(A) Heatmap showing the correlations (Spearman’s ρ) between ConsensusTME-
based values and aneuploidy scores (Taylor et al., 2018) across major cancer 
types. 
(B) Heatmap showing the correlations (Spearman’s ρ) between ConsensusTME-
based values and aneuploidy scores (Taylor et al., 2018) across in BRCA 
subtypes, which show positive correlations in claudin-low. 
 
Fig. S4. Differences of inferred immune/stromal cell content between 
primary tumors with low and high levels of CD274/PDL1 expression. 
Related to Figure 1. The graphs show the median cell content value in each 
group and the significance of the difference (Wilcoxon test P value). 
 
Fig. S5. Differences of inferred immune/stromal cell content between 
primary tumors with low and high levels of CD279/PDCD1 expression. 
Related to Figure 1. The graphs show the median cell content value in each 
group and the significance of the difference (Wilcoxon test P value). 
 
Fig. S6. Correlations between inferred blood immune cell contents and 
measures from fluorescence-activated cell sorting in blood samples. 
Related to Figure 1. Forest plot showing correlation estimates and 95% CIs of 
each inferred cell type (data from whole blood samples of healthy adults; n = 12, 
GEO GSE127813).  
 
Fig. S7. Correlations between inferred immune/stromal cell tissue 
contents and single cells used to generate pseudo-bulk breast tumors. 
Related to Figure 1. Each panel shows the correlation between immune cell 
signature scores (Y-axis) and the number of cells (X-axis) used to generate 100 
pseudo-bulk breast tumors (data from Gene Expression Omnibus reference 
GSE75688). The trend lines, Spearman’s correlations and P values are shown. 
 
Fig. S8. Correlations between immune/stromal cell tissue contents and 
expression of immune benchmark genes. Related to Figure 1. Top panel, 
distribution of PCCs using data from normal TCGA tissue. Bottom panel, 
distribution of PCCs using data from primary tumors of TCGA. Mean PCCs and 
95% CIs are shown. 
 
Fig. S9. Correlations between immune cell signatures and pathway 
signaling-inferred activities. Related to Figure 1. Unsupervised clustering of 
the correlation coefficients between inferred cell contents (Y-axis) and KEGG 
pathway activities (X-axis). Differentiated clusters in normal tissue are marked 
by red-outlined rectangles. 
 
Fig. S10. Gene targets of eQTL recognized in isQTLs are frequently 
correlated with the corresponding immune/stromal cell signatures. 
Related to Figure 2. Distributions of random gene sets (same gene set size 
and equivalent comparisons for each signature and TCGA setting) relative to 
the number of significant correlations between eQTL-target and immune/stromal 
signatures. Left- and right-hand panels show results for the first and second 
isQTL sets presented in the main text, respectively. Empirical test probabilities 
are shown. 
 
Fig. S11. Minimal correlation estimates to detect significant signature-
PRS associations. Related to Figure 3. Left and right panels show the lowest 
correlations required in each normal and primary tumor setting, respectively, to 
detect nominal (P < 0.05) associations given the TCGA sample sizes. 
 
Fig. S12. LUAD and LUSC PRS correlations with NK cell content. Related 
to Figure 3. Top panels, positive correlations between NK cell content in 
primary tumors of LUAD and LUSC, and the corresponding PRSs. The 
adjusted-R2 and P values of the linear regression model are shown. Bottom 
panels, correlation trends of patients stratified by smoking status, as depicted in 
the insets. The estimate for LUAD cases classified as current smokers was 
found to be significantly less than zero (r = -0.12, P = 0.012). 
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Transparent Methods 
TCGA data 
Clinical and gene expression (RNA-seq fragments per kilobase of transcript per million 
mapped reads (FPKM) upper quartile normalized (UQ)) data from The Cancer Genome 
Atlas (TCGA) projects were obtained from the Genomic Data Commons Data Portal 
(https://portal.gdc.cancer.gov) and from the corresponding publications. Genetic data at 
the individual level were obtained following approval by the dbGaP Data Access 
Committee (project #11689). Metastases and recurrent tumors were excluded from this 
study, making normal tissue (blood or solid tissue) and primary tumor samples the focus 
of the analyses. The cancer types are named using the corresponding TCGA study 
abbreviations (https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-
abbreviations). For normal tissue, according to the TCGA protocols, these samples were 
collected > 2  cm from the tumor margin and/or did not contain tumor identified by 
histopathological review. The protein expression measures of CD26 and TFCR 
corresponded to those obtained by TCGA using reverse-phase protein arrays (RPPAs; 
level 4 data, https://tcpaportal.org/tcpa/). The COAD subtypes were defined based 
genomic/genetic alterations (chromosomal instability (CIN), genomic stable (GS), and 
microsatellite instability (MSI) tumors) and on molecular features (consensus molecular 
subtypes, CMS1-4) (Guinney et al., 2015).  
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Cancer risk variants 
The variants were compiled from the GWAS Central (Beck et al., 2014) and GWAS 
Catalog (Buniello et al., 2019) databases, and by literature searches using the PubMed 
MeSH terms “GWAS”, “association”, “cancer”, and “risk”. The variants are listed in Table 
S1. The UK Biobank GWAS results were taken from the public repository at 
http://www.nealelab.is/uk-biobank. 
 
Benchmark immune genes 
These genes were compiled from The Immunological Genome Project (ImmGen) (Shay 
and Kang, 2013) and CellMarker (Zhang et al., 2019) databases, and by a literature 
search using the MeSH terms corresponding to the specific immune cell types 
represented by the gene expression signatures. The benchmarks and their cell type 
assignments are included in Table S3. 
 
Genotype data and imputation 
Bulk genotyping data corresponding to the Affymetrix Genome-Wide Human SNP 6.0 
Array were downloaded from the TCGA legacy archive (https://gdc-
portal.nci.nih.gov/legacy-archive/). Of the initial normal tissue and primary tumor 
samples (n = 16,599), those corresponding to individuals of self-reported non-white 
origin (n = 4,770), and those of non-European origin based on principal component 
analysis using variants intersected in the 1000 Genome Project phase III (n = 2,598) 
were excluded from subsequent analyses; these filters were applied because summary 
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statistics of the GWASs used in this study are strongly biased towards populations of 
European origin. Normal and tumor samples were then examined separately for 
duplicates and up to third-degree relatives (kinship cutoff = 0.05), which resulted in the 
exclusion of an additional 672 samples. In the joint dataset, 765 samples were also 
excluded because they showed a gender mismatch in an analysis of pseudoautosomal 
genomic regions. Considering genetic variants, 108 samples that deviated by four or 
more standard deviations from the mean heterozygosity rate were also excluded. For 
imputation, variants were excluded if they fulfilled any of the following criteria: they 
mapped to chromosome Y, pseudoautosomal regions or the mitochondrial genome; they 
had a call rate < 100%; their minor allele frequency was < 0.01; they departed from 
Hardy–Weinberg equilibrium (P < 5x10-6); or they mapped to AT-CG sites. Finally, 7,686 
samples (4,154 normal, comprising 3,287 blood-derived and 867 solid-tissue samples; 
and 3,532 primary tumors, of which 94.4% were paired) and 589,101 variants were 
retained for subsequent analyses. Imputation was performed using the Shape-IT V2 
(Delaneau et al., 2008) and IMPUTE2 (Howie et al., 2009) algorithms, and the 1000 
Genome Project Phase III panel as reference. Poorly imputed variants (accuracy score < 
0.7) were excluded from subsequent analyses. A standard cutoff dose was applied to 
calculate genotypes using a hard-call threshold of 0.1 (i.e., 0 – 0.1, 0.9 – 1.1, 1.9 – 2.0 
for reference homozygote, heterozygous and alternative homozygous genotypes, 
respectively). 
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Immune/stromal cell signatures 
Immune/stromal cell gene expression signatures for each TCGA cancer setting were 
computed using the ConsensusTME method (Jiménez-Sánchez et al., 2019), which was 
provided available as an R package (https://github.com/cansysbio/ConsensusTME). Ten 
single-cell breast cancer signatures (Azizi et al., 2018) were included in the TCGA BRCA 
analyses. Therefore, 18 signatures were examined in each normal tissue and primary 
tumor setting, except for normal breast and breast cancer tissue, for which a total of 28 
signatures were analyzed. The signature scores were computed using the single-sample 
Gene Set Expression Analysis (ssGSEA) algorithm calculated within the Gene Set 
Variation Analysis (GSVA) software (Hänzelmann et al., 2013). These scores were 
calculated for normal tissue and primary tumors, but not for blood samples, since data 
from blood are limited to germline genotypes. Genes whose expression was 
uninformative in more than half the samples in a given setting were excluded from the 
signature calculations; otherwise, missing data were assigned the average value of the 
informative samples. Evaluation of signature scores computed by two different methods 
—ssGSEA and summing normalized gene expression Z-scores— revealed global 
coherence, whereby Pearson correlation coefficients (PCCs) were > 0.80 in 99% 
(571/578) of the score comparisons. To select independent signatures in each normal 
and cancer setting, we performed a principal component analysis using the prcomp 
function in R. Components with eigenvalues > 1 were retained to study quantitative trait 
loci (subsequent sections). Estimates of immune-related pathway activities were 
calculated using directed graphs from the Kyoto Encyclopedia of Genes and Genomes 
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(KEGG, https://www.genome.jp/kegg/). Briefly, gene expression profiles were converted 
into pathway module activity scores by taking into account the chain of reactions from a 
defined molecular input to a specific molecular output (Cubuk et al., 2018). The 84-gene 
signature linked to SH2B3 included the genes differentially expressed in Sh2b3-null cells 
and that participate in genetic and/or protein interactions to this gene/protein (Huan et 
al., 2015); SH2B3 was excluded from this signature for subsequent analyses. 
 
Pseudo-bulk breast tumors 
To generate 100 pseudo-bulk breast tumors, we used the single-cell RNA-seq data from 
the Gene Expression Omnibus (GEO) reference GSE75688 (Chung et al., 2017) and 
aggregated read counts using the aggregateData function in R 
(https://github.com/HelenaLC/muscat). Each simulated sample of 100 cells was forced 
to include >50% tumor cells (average 75.3%, 95% CI 72.53 – 77.93%). For non-tumoral 
cells, 10% of them were fixed as stromal (bulk average 7.22%, 95% CI 6.22 – 8.36%), 
while the other 90% were a random combination of B cells (average 5.16%, 95% CI 4.28 
– 6.28%), T cells (average 6.21%, 95% CI 5.05 – 7.48%), and myeloid cells (average 
6.11%, 95% CI 5.05 – 7.39%). Most of the myeloid cells were originally assigned to 
macrophages (Chung et al., 2017). 
 
Quantitative trait loci of immune/stromal cell tissue content 
The germline genetic calls corresponded to genotype data obtained from blood or 
normal tissue samples. For cases with both types of sample, the variants with discordant 
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calls were excluded from subsequent analyses. As specified above, the somatic genetic 
calls corresponded to primary tumors only. The immune/stromal cell-content quantitative 
trait loci (isQTL) were analyzed using the R/qtl2 package in R (Broman et al., 2019). 
These analyses included the covariates of gender (when informative), age at diagnosis, 
tumor stage and histology. The Haley–Knott regression method was used to compute 
the log odds (LOD) of the associations between genetic variants and immune/stromal 
cell scores. One thousand permutations were performed in each setting to obtain 
significance thresholds (Manichaikul et al., 2007) and the variant-signature associations 
with empirical values of P < 0.05 were considered significant isQTL. The gene targets 
were defined according to the genomic location of the identified variants. Additional 
targets were identified by analyzing all variants correlated (r2 > 0.8, 1000 Genomes 
phase 3, version 5) with each isQTL and intersect them with various functional genomic 
data, including promoter capture Hi-C (Javierre et al., 2016), annotated enhancers 
(Hnisz et al., 2013, p.), and eQTL (Schmiedel et al., 2018) from B cells, monocytes, and 
CD4+ and CD8+ T cells. In addition, correlated variants were queried using the Ensembl 
Variant Effect Predictor (McLaren et al., 2016) for potential effects on protein coding 
sequences. 
 
Computation of PRSs 
The PRSs were compiled from the literature and computed by summing the products of 
the per-allele LOD ratio assigned to each risk variant, and the corresponding allele 
dosage, for the total number of variants initially defined for each PRS. There was no 
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previous evidence of significant interactions or deviations from a log-additive model in 
BRCA PRSs (Mavaddat et al., 2019), but it is not known for other cancers. In the 
analyses of BRCA, OV (no normal tissue data available), and PRAD PRSs, two sets 
were analyzed, both based on GWAS-identified variants: set #1 (hereafter PRSs-1), 
which corresponded to scores derived from large collections of GWAS cohorts and 
validated in independent studies (Mavaddat et al., 2019); and set #2 (hereafter PRSs-2), 
which corresponded to scores derived from a phenome-wide longitudinal study using 
electronic health records collected by the Michigan Genomics Initiative (Fritsche et al., 
2018). In both sets, PRSs were developed for all BRCA patients, and separately for the 
estrogen receptor (ER)-positive and ER-negative subtypes. The number of initial 
variants in these BRCA PRSs and those included in our study, based on available 
genotypes and obtained imputations were 307 and 185 for PRSs-1, and 3,820 and 
3,629 for PRSs-2. As expected, the PRSs from the two sets were found to be positively 
correlated using germline or primary tumor data: BRCA PRSs PCCs = 0.60 – 0.66, P < 
10-5; OV tumors PRSs PCC = 0.72, P < 10-25 (serous PCC = 0.72); and PRAD PRSs 
PCCs = 0.23 – 0.99, P < 0.01. The Michigan Genomics Initiative also provided PRSs for 
seven other cancer types, and the number of variants originally included and analyzed in 
this study were, respectively: 103 and 21 for PRAD; 42 and 41 for COAD; 16 and 16 for 
BLCA and SKCM; 15 and 15 for OV; 9 and 9 for GBM, LUAD and LUSC; 8 and 7 for 
THCA; and 7 and 6 for KIRC. 
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Cell signature associations with PRSs 
The bestNormalize package in R (https://github.com/petersonR/bestNormalize) was 
used to normalize the cell signature values. The transformation that produced the lowest 
value from the Pearson’s statistic divided by the degrees of freedom was taken to 
indicate the best function. The error distributions of the models and Q-Q plots were 
examined individually. The parameters of each signature transformation are provided in 
Table S10. Outliers were identified using the interquartile range rule and excluded from 
subsequent analyses; these were < 5% in all settings. Normalized signature values were 
used as dependent variables in a linear regression analysis relative to the PRSs. 
Stepwise analyses including covariates of gender, tumor stage and histology were 
performed, and the best model was selected based on the Akaike information criterion 
(AIC). For normal tissue, only those studies with at least 50 informative samples were 
analyzed. The small number of samples in each setting meant that these analyses could 
only detect significant (nominal P < 0.05) correlation estimates > 0.27 and > 0.09 in 
normal breast tissue and BRCA, and stronger correlations would be required in all other 
settings if nominal significance were to be reached (Fig. S11). The significance of the 
associations was corrected for multiple testing using the false-discovery rate (FDR) 
method. 
 
Cell signature associations with age at diagnosis 
The associations between the cell signature scores (dependent variables) and age at 
diagnosis were evaluated by multiple linear regression, including gender and tumor 
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stage as covariates, the best model being determined from an AIC-based stepwise 
selection algorithm. The statistical significances of the associations were corrected for 
multiple testing separately in normal tissue and primary tumor analyses (since the 
expected effects were the opposite of what they proved to be) using the FDR method. 
 
Breast cancer risk in BRCA1/2-mutation carriers  
Analyses were performed using data from the OncoArray and Collaborative Oncological 
Gene-environment Study (iCOGS) consortiums with the participation of the Consortium 
of Investigators of BRCA1/2 Modifiers (CIMBA). The OncoArray and iCOGS designs, 
quality controls, and statistical analyses have been described previously (Milne et al., 
2017). Summary statistics from the retrospective likelihood method are reported. 
 
Analysis of blood cell parameters and age at diagnosis of breast cancer 
Clinical and histopathological data from breast cancer patients were compiled through 
manual curation of hospital records of the Catalan Institute of Oncology, L’Hospitalet del 
Llobregat (Barcelona, Catalonia, Spain). Patients were randomly selected from health 
records collected between 2009 and 2014. The compiled data included date of birth, 
age, gender (only women selected), date at diagnosis, tumor stage, subtype and/or ER 
status, and date at initial-diagnostic blood test. The blood test parameters analyzed were 
the normalized numbers (x109/L) of basophils, eosinophils, leucocytes, lymphocytes, 
monocytes, neutrophils, and platelets. Linear regressions of each of these parameters 
	 10	
on age at diagnosis, including tumor stage and subtype as covariates, were performed. 
The IDIBELL’s Research Ethics Committee approved this study (reference PR066/20). 
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